2024–2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims
The 2024-2025 formulation of BNT162b2 COVID-19 vaccine provided significant protection, particularly for older adults, in mid-season estimates. This study is registered on clinicaltrials.gov as NCT06923137.
Authors
- Laura Puzniak (ORCID: https://orcid.org/0000-0001-8697-9683)
- Aimin Zhou (ORCID: https://orcid.org/0000-0003-1015-9966)
- Jazmine Mateus (ORCID: https://orcid.org/0000-0003-0794-6504)
- Santiago M. C. Lopez (ORCID: https://orcid.org/0000-0001-7714-1707)
- Kathleen M. Andersen (ORCID: https://orcid.org/0000-0003-2670-800X)
- Tiange Yu (ORCID: https://orcid.org/0009-0009-8854-7142)
- Tara Ahi
Institutions
- Pfizer (United States) (US)
Publication Details
- Journal
- Vaccine
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127534
- Citations
- 3
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 4.17
Funders
- Pfizer